Basilea Pharmaceutica, a spin-off from Switzerland pharmaceutical company Roche, has sold eczema drug Toctino to Stiefel, part of GlaxoSmithKline for £146m ($228.4m) upfront payments and up to £50m in milestone payments. Basilea was founded in 2000 as a spin from Swiss pharmaceutical group Roche and it went public on the SIX Swiss Exchange in 2004.…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
